A recent study reveals that patients who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional lifestyle plans.
Published data in a major medical journal shows that while overweight individuals often shed substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"People using these medications must be aware of the potential of fast rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to starting weight within about 18 months.
Analyzing Treatments
The analysis, which examined 37 of trials involving thousands of participants, compared the outcomes of these new drugs with other pills.
Researchers emphasize that people who lose weight through dieting generally see a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Doctors suggest the mechanism of the injections explains the accelerated rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating far more likely."
A Chronic Issue?
Medical guidelines advise the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of relapse, the treatment might need to be life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Experiences
Individuals who have stopped the jabs report a sudden resurgence of hunger.
"I experienced a switch that goes on and I was suddenly extremely hungry," recalled a patient.
The struggle is compounded if patients have not established sustainable lifestyle or habit modifications during treatment.
Significant Interest
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is greater among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians caution that while the jabs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on integrated behavioural support.
